Authors
Latest:
Dr Sallman on the Significance of the FDA Approval of Frontline Luspatercept for Lower-Risk MDSDavid Sallman, MD, discusses the clinical implications of the 2023 FDA approval of luspatercept for patients with very low– to intermediate-risk MDS.
Latest:
Dr. Schenkein on AG-221 for the Treatment of AMLDavid Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).
Latest:
Dr Sher on the Efficacy and Safety of Daily Adaptive Radiotherapy in HNSCCDavid Sher, MD, discusses efficacy outcomes with daily adaptive radiotherapy with 1-mm planning target volume margins in patients with head and neck squamous cell carcinoma.
Latest:
Oncology Experts Preview Top Abstracts From the 2024 ESMO CongressExperts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.
Latest:
Dr. Marshall on ASCENDE-RT Trial for Prostate CancerDavid T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.
Latest:
MEDCAC Ruling on Lung Cancer ScreeningThe MEDCAC ruling will likely lead to non-coverage of lung cancer screening with low dose CT scans for Medicare and Medicaid beneficiaries.
Latest:
Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.
Latest:
Dipping a Toe Into Care ManagementFee-for-service remains the primary driver of patient revenue for the majority of oncology practices across the country, and the same is true for The Center for Cancer and Blood Disorders.
Latest:
Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast CancerDawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.
Latest:
Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer PatientsDawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.
Latest:
Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast CancerDawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.
Latest:
Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and TeacherLong before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.
Latest:
Dr. Attai on the Challenges With Implementing Survivorship Care PlansDeanna J. Attai, MD, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), breast surgeon at UCLA Health, discusses studies exploring the challenges with survivorship care plan implementation for patients with cancer in an interview during the 2017 ASCO Annual Meeting.
Latest:
Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate CancerDeborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.
Latest:
Addressing AYA Cancer Requires a Tailored Approach to PracticeInvestigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.
Latest:
Dr. Krakow on Genetic Testing in Ovarian CancerDeborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.
Latest:
Dr. Patt on the Role of Sacituzumab Govitecan in TNBCDebra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.
Latest:
Federal Indecisiveness Belies Significant Changes in Medicaid Policy State by StateToday’s healthcare landscape is rapidly evolving, with many trends emerging and policy changes under consideration that have far-reaching implications for cancer care.
Latest:
Mayo Study Characterizes Pembrolizumab-Induced ThyroiditisAbnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.
Latest:
Dr Tripathy on Real-World HER2 Testing and CDK4/6 Inhibitor Use in HER2+ Breast CancerDebu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.
Latest:
Dr. Tripathy on the Evolving Treatment Landscape of HER2+ Breast CancerDebu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.
Latest:
Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of MalnutritionDeclan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.
Latest:
Dr. Kapoor on LUGPA's Legislative AdvocacyDeepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.
